Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up of Cellgram-LC in Alcoholic Liver Cirrhosis
NCT05093881Recruiting
- Sponsor
- Pharmicell Co., Ltd.
- Start
- Aug 2021
- Primary completion
- Aug 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of Cellgram-LC in alcoholic liver cirrhosis, sponsored by Pharmicell Co., Ltd. Primary endpoints: Rate of Adverse Events of Special Interest at 5 years and Rate of Liver Transplant at 5 years. Started Aug 2021; status: recruiting.
02
Drugs
Cellgram-LC
03
Conditions
alcoholic liver cirrhosis
Beyond the preview
Go deeper on NCT05093881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05093881.